InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of Amyotrophic Lateral Sclerosis
InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of
Pierre Miniou Francina Agosti Philippe Guedat Reportable Inc French Regulatory Authority Inflectis Bioscience
Source: parisguardian.com